Dr. Min Yan 闫敏
Chief Physician
Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical management of breast cancer, including preoperative neoadjuvant therapy, postoperative adjuvant therapy for early-stage disease, and comprehensive treatment for recurrent or metastatic breast cancer.
Dr. Yan holds an MD and has over 20 years of clinical experience in medical oncology for breast cancer. Dr. Yan serves as Deputy Director of the Henan Breast Cancer Diagnosis and Treatment Center and Director of the Seventh Ward (Medical Oncology) at Henan Cancer Hospital. Dr. Yan has authored or co-authored 73 papers and contributed to five monographs. Dr. Yan has led 22 clinical studies and participated in over 100 multicenter trials. Dr. Yan contributed to the CSCO Breast Cancer Diagnosis and Treatment Guidelines and serves as a chief expert for multidisciplinary consultations.
Professional roles
- Vice Chair, Breast Cancer Group, Precision Medicine and Tumor MDT Professional Committee, Chinese Research Hospital Association
- Standing Committee Member, Breast Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Breast Disease Research Center Professional Committee, China Women Doctors Association
- Member, Multiple Primary and Unknown Primary Tumor Expert Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Yan Min). Papers usually list the name as Min Yan or Yan M.
Selected publications
99 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Chin Med J (Engl), 2026 (senior author): Addition of angiogenesis inhibitors to CDK4/6 inhibitors and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer. PubMed 42421507
- BMJ Support Palliat Care, 2026 (senior author): Distress thermometer and determinants of psychological distress in metastatic breast cancer. PubMed 40537178
- BMC Med, 2026 (senior author): Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study. PubMed 41593669
- Clin Ther, 2025 (senior author): Trastuzumab Deruxtecan and Sacituzumab Govitecan for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer: A Cost-Effectiveness Analysis. PubMed 40544074
- JAMA Oncol, 2025 (first author): Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. PubMed 40569584
- J Cancer Res Clin Oncol, 2025 (senior author): Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons. PubMed 39979499
- EClinicalMedicine, 2024 (first author): Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial. PubMed 39380967
- Chin Med J (Engl), 2024 (senior author): Effect of GnRH analogs in advanced male breast cancer: 10-year experience from the Henan Breast Cancer Center and literature review. PubMed 38445362
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion